These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25145639)

  • 1. For the Sake of Justice: Should We Prioritize Rare Diseases?
    Juth N
    Health Care Anal; 2017 Mar; 25(1):1-20. PubMed ID: 25145639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orphan drugs: expensive yet necessary.
    Hyry HI; Roos JC; Cox TM
    QJM; 2015 Apr; 108(4):269-72. PubMed ID: 25434052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
    Sheehan M
    BMJ; 2005 Nov; 331(7525):1144-5. PubMed ID: 16282416
    [No Abstract]   [Full Text] [Related]  

  • 5. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are drugs for rare diseases "essential"?
    Reidenberg MM
    Bull World Health Organ; 2006 Sep; 84(9):686. PubMed ID: 17128329
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.
    Park T; Griggs SK; Suh DC
    BioDrugs; 2015 Aug; 29(4):259-74. PubMed ID: 26263903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limits on use of health economic assessments for rare diseases.
    Hyry HI; Stern AD; Cox TM; Roos JC
    QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

  • 12. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outrageous prices of orphan drugs: a call for collaboration.
    Luzzatto L; Hyry HI; Schieppati A; Costa E; Simoens S; Schaefer F; Roos JCP; Merlini G; Kääriäinen H; Garattini S; Hollak CE; Remuzzi G;
    Lancet; 2018 Sep; 392(10149):791-794. PubMed ID: 30037734
    [No Abstract]   [Full Text] [Related]  

  • 14. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orphan drugs and the NHS: should we value rarity?
    McCabe C; Claxton K; Tsuchiya A
    BMJ; 2005 Oct; 331(7523):1016-9. PubMed ID: 16254305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Orphan drugs: towards an economic evaluation].
    Holué C
    Rev Prat; 2012 Jan; 62(1):91-4. PubMed ID: 22335077
    [No Abstract]   [Full Text] [Related]  

  • 17. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
    Schlander M; Beck M
    Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods.
    Bourke SM; Plumpton CO; Hughes DA
    Value Health; 2018 May; 21(5):538-546. PubMed ID: 29753350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Principle of protection and treatment of rare genetic diseases in Brazil: the case of lysosomal storage disorders].
    Boy R; Schramm FR
    Cad Saude Publica; 2009 Jun; 25(6):1276-84. PubMed ID: 19503958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.